NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

Eisai's breast cancer treatment Halaven will remain on the Cancer Drugs Fund after the firm's appeal was granted. In January, the Cancer Drugs Fund (CDF) announced that Halaven (eribulin) would be ...

WOODCLIFF LAKE, N.J., Jan. 11, 2021 /PRNewswire/ -- Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symp ...

And more pharma news updates from Pharmalittle.

CNW/ - Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, ...

Japan's Eisai Co Ltd will surrender its rights to share profit from Aduhelm, the Alzheimer's treatment drug jointly developed with U.S. partner Biogen Inc , and instead receive sales royalties ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ...

Eisai is hoping to present enough evidence to the FDA to convince regulators that the benefit of treatment with lecanemab outweighs the risks and avoid a warning on the drug’s potential label.

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

Eisai and Biogen sought the Food and Drug Administration’s accelerated approval for the amyloid beta-busting drug, lecanemab. Sold under the brand name Leqembi, the drug is priced at $26,500 per ...